Q2 2024 EPS Estimates for BrainsWay Ltd. Lifted by Analyst (NASDAQ:BWAY)

BrainsWay Ltd. (NASDAQ:BWAY) – Investment analysts at Northland Capmk increased their Q2 2024 earnings per share (EPS) estimates for shares of BrainsWay in a research report issued to clients and investors on Wednesday, May 8th. Northland Capmk analyst C. Byrnes now expects that the company will earn $0.00 per share for the quarter, up from their prior estimate of ($0.01). The consensus estimate for BrainsWay’s current full-year earnings is ($0.02) per share. Northland Capmk also issued estimates for BrainsWay’s Q3 2024 earnings at $0.01 EPS.

Several other equities research analysts have also commented on the stock. Oppenheimer boosted their price objective on shares of BrainsWay from $10.00 to $11.00 and gave the stock an “outperform” rating in a research note on Thursday. HC Wainwright upped their price target on BrainsWay from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Thursday.

BrainsWay Price Performance

NASDAQ:BWAY opened at $5.33 on Friday. The firm’s 50-day moving average price is $5.51 and its 200-day moving average price is $5.72. The company has a market capitalization of $88.69 million, a PE ratio of -41.00 and a beta of 1.18. BrainsWay has a 1-year low of $1.38 and a 1-year high of $7.61.

BrainsWay (NASDAQ:BWAY) last released its quarterly earnings results on Wednesday, March 6th. The company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.02. The company had revenue of $9.03 million for the quarter, compared to analyst estimates of $8.40 million. BrainsWay had a negative return on equity of 3.98% and a negative net margin of 4.83%. During the same period in the previous year, the company posted ($0.12) earnings per share.

Institutional Trading of BrainsWay

A number of institutional investors and hedge funds have recently bought and sold shares of BWAY. AIGH Capital Management LLC grew its holdings in shares of BrainsWay by 6.5% during the third quarter. AIGH Capital Management LLC now owns 1,355,022 shares of the company’s stock valued at $5,474,000 after buying an additional 83,262 shares during the last quarter. Acadian Asset Management LLC purchased a new position in shares of BrainsWay in the third quarter worth $28,000. Worth Venture Partners LLC lifted its holdings in shares of BrainsWay by 6.0% during the third quarter. Worth Venture Partners LLC now owns 336,643 shares of the company’s stock valued at $1,360,000 after purchasing an additional 19,045 shares in the last quarter. Legato Capital Management LLC bought a new position in shares of BrainsWay during the fourth quarter valued at $542,000. Finally, Jump Financial LLC purchased a new stake in shares of BrainsWay during the fourth quarter valued at $207,000. 30.11% of the stock is currently owned by institutional investors.

BrainsWay Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.